Voyager Therapeutics (VYGR) Projected to Post Earnings on Wednesday

Voyager Therapeutics (NASDAQ:VYGR) is expected to be releasing its earnings data before the market opens on Wednesday, February 26th. Analysts expect Voyager Therapeutics to post earnings of ($0.35) per share and revenue of $16.58 million for the quarter.

Voyager Therapeutics Price Performance

NASDAQ:VYGR opened at $4.10 on Tuesday. The firm has a market capitalization of $223.97 million, a price-to-earnings ratio of 5.77 and a beta of 0.91. Voyager Therapeutics has a 1 year low of $4.00 and a 1 year high of $10.66. The business has a 50 day simple moving average of $5.32 and a 200-day simple moving average of $6.07.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on VYGR shares. Canaccord Genuity Group reissued a “buy” rating and set a $14.00 price target on shares of Voyager Therapeutics in a research note on Thursday, November 14th. StockNews.com lowered Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research note on Monday, January 27th. Wedbush reissued an “outperform” rating and set a $9.00 price target (down from $11.00) on shares of Voyager Therapeutics in a research note on Tuesday, February 11th. Finally, Citigroup started coverage on Voyager Therapeutics in a research note on Monday, December 2nd. They set a “buy” rating and a $12.00 price target for the company. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $15.72.

Insiders Place Their Bets

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the firm’s stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the transaction, the chief operating officer now directly owns 112,328 shares in the company, valued at $634,653.20. This trade represents a 5.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold 10,778 shares of company stock worth $58,548 in the last ninety days. 4.53% of the stock is owned by company insiders.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.